Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of INCB054707 (Povorcitinib) in Hidradenitis Suppurativa
NCT03607487Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Started Oct 2018; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03607487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607487.